Thomas W. Beetham - Net Worth and Insider Trading
Thomas W. Beetham Net Worth
The estimated net worth of Thomas W. Beetham is at least $7 Million dollars as of 2024-11-05. Thomas W. Beetham is the EVP & Chief Legal Officer of Kiniksa Pharmaceuticals International PLC and owns about 297,523 shares of Kiniksa Pharmaceuticals International PLC (KNSA) stock worth over $6 Million. Thomas W. Beetham is the COO of Viridian Therapeutics Inc and owns about 6,000 shares of Viridian Therapeutics Inc (VRDN) stock worth over $135,870. Thomas W. Beetham is also the See Remarks of Magenta Therapeutics Inc and owns about 13,897 shares of Magenta Therapeutics Inc (MGTA) stock worth over $9,722. Details can be seen in Thomas W. Beetham's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas W. Beetham has not made any transactions after 2024-09-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas W. Beetham
Thomas W. Beetham Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas W. Beetham owns 3 companies in total, including Kiniksa Pharmaceuticals International PLC (KNSA) , Magenta Therapeutics Inc (MGTA) , and Viridian Therapeutics Inc (VRDN) .
Click here to see the complete history of Thomas W. Beetham’s form 4 insider trades.
Insider Ownership Summary of Thomas W. Beetham
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International PLC | 2021-02-03 | 10 percent owner & Chief Legal Officer |
| MGTA | Magenta Therapeutics Inc | 2021-09-16 | See Remarks |
| VRDN | Viridian Therapeutics Inc | 2024-09-27 | Chief Operating Officer |
Thomas W. Beetham Latest Holdings Summary
Thomas W. Beetham currently owns a total of 3 stocks. Among these stocks, Thomas W. Beetham owns 297,523 shares of Kiniksa Pharmaceuticals International PLC (KNSA) as of February 3, 2021, with a value of $6 Million and a weighting of 97.81%. Thomas W. Beetham owns 6,000 shares of Viridian Therapeutics Inc (VRDN) as of September 27, 2024, with a value of $135,870 and a weighting of 2.05%. Thomas W. Beetham also owns 13,897 shares of Magenta Therapeutics Inc (MGTA) as of September 16, 2021, with a value of $9,722 and a weighting of 0.15%.
Latest Holdings of Thomas W. Beetham
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International PLC | 2021-02-03 | 297,523 | 21.84 | 6,497,902 |
| VRDN | Viridian Therapeutics Inc | 2024-09-27 | 6,000 | 22.65 | 135,870 |
| MGTA | Magenta Therapeutics Inc | 2021-09-16 | 13,897 | 0.70 | 9,722 |
Holding Weightings of Thomas W. Beetham
Thomas W. Beetham Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas W. Beetham has made a total of 5 transactions in Kiniksa Pharmaceuticals International PLC (KNSA) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Kiniksa Pharmaceuticals International PLC is the sale of 2,477 shares on February 3, 2021, which brought Thomas W. Beetham around $54,717.
According to the SEC Form 4 filings, Thomas W. Beetham has made a total of 1 transactions in Viridian Therapeutics Inc (VRDN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Viridian Therapeutics Inc is the acquisition of 5,000 shares on September 27, 2024, which cost Thomas W. Beetham around $117,050.
According to the SEC Form 4 filings, Thomas W. Beetham has made a total of 1 transactions in Magenta Therapeutics Inc (MGTA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Magenta Therapeutics Inc is the sale of 6,103 shares on September 16, 2021, which brought Thomas W. Beetham around $41,073.
Insider Trading History of Thomas W. Beetham
- 1
Thomas W. Beetham Trading Performance
GuruFocus tracks the stock performance after each of Thomas W. Beetham's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas W. Beetham is %. GuruFocus also compares Thomas W. Beetham's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas W. Beetham within 3 months outperforms times out of transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas W. Beetham's insider trading performs compared to the benchmark.
Performance of Thomas W. Beetham
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -1.2 |  | | | | |
| Relative Return to S&P 500(%) | -2.42 | | | | | |
Thomas W. Beetham Ownership Network
Ownership Network List of Thomas W. Beetham
Ownership Network Relation of Thomas W. Beetham
Thomas W. Beetham Owned Company Details
What does Kiniksa Pharmaceuticals International PLC do?
Who are the key executives at Kiniksa Pharmaceuticals International PLC?
Thomas W. Beetham is the 10 percent owner & Chief Legal Officer of Kiniksa Pharmaceuticals International PLC. Other key executives at Kiniksa Pharmaceuticals International PLC include Chief Business Officer Eben Tessari , Group VP & Rilonacept GM Ross Moat , and Chief Medical Officer John Paolini .
Kiniksa Pharmaceuticals International PLC (KNSA) Insider Trades Summary
Over the past 18 months, Thomas W. Beetham made no insider transaction in Kiniksa Pharmaceuticals International PLC (KNSA). Other recent insider transactions involving Kiniksa Pharmaceuticals International PLC (KNSA) include a net sale of 150,848 shares made by John Paolini , a net sale of 219,460 shares made by Sanj K Patel , and a net sale of 52,000 shares made by Eben Tessari .
In summary, during the past 3 months, insiders sold 181,198 shares of Kiniksa Pharmaceuticals International PLC (KNSA) in total and bought 0 shares, with a net sale of 181,198 shares. During the past 18 months, 539,163 shares of Kiniksa Pharmaceuticals International PLC (KNSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 539,163 shares.
Kiniksa Pharmaceuticals International PLC (KNSA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kiniksa Pharmaceuticals International PLC Insider Transactions
Thomas W. Beetham Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas W. Beetham. You might contact Thomas W. Beetham via mailing address: C/o Kiniksa Pharmaceuticals, Ltd., Clarendon House, 2 Church Street, Hamilton D0 Hm11.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
